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Relationship of National Institutes of Health Stroke Scale to 30-Day
Mortality in Medicare Beneficiaries With Acute Ischemic Stroke
Gregg C. Fonarow, MD; Jeffrey L. Saver, MD; Eric E. Smith, MD, MPH; Joseph P. Broderick, MD; Dawn O. Kleindorfer, MD; Ralph L.
Sacco, MD; Wenqin Pan, PhD; DaiWai M. Olson, PhD; Adrian F. Hernandez, MD, MHS; Eric D. Peterson, MD, MPH; Lee H. Schwamm, MD
Background— The National Institutes of Health Stroke Scale (NIHSS), a well-validated tool for assessing initial stroke severity, has
previously been shown to be associated with mortality in acute ischemic stroke. However, the relationship, optimal categorization,
and risk discrimination with the NIHSS for predicting 30-day mortality among Medicare beneficiaries with acute ischemic stroke
has not been well studied.
Methods and Results—Weanalyzed data from33102 fee-for-serviceMedicare beneficiaries treated at 404GetWith TheGuidelines-
Stroke hospitals between April 2003 and December 2006 with NIHSS documented. The 30-day mortality rate by NIHSS as a
continuous variable and by risk-tree determined or prespecified categories were analyzed, with discrimination of risk quantified
by the c-statistic. In this cohort, mean age was 79.0 years and 58% were female. The median NIHSS score was 5 (25th to 75th
percentile 2 to 12). There were 4496 deaths in the first 30 days (13.6%). There was a strong graded relation between increasing
NIHSS score and higher 30-day mortality. The 30-day mortality rates for acute ischemic stroke by NIHSS categories were as follows:
0 to 7, 4.2%; 8 to 13, 13.9%; 14 to 21, 31.6%; 22 to 42, 53.5%. A model with NIHSS alone provided excellent discrimination whether
included as a continuous variable (c-statistic 0.82 [0.81 to 0.83]), 4 categories (c-statistic 0.80 [0.79 to 0.80]), or 3 categories
(c-statistic 0.79 [0.78 to 0.79]).
Conclusions— The NIHSS provides substantial prognostic information regarding 30-day mortality risk in Medicare beneficiaries
with acute ischemic stroke. This index of stroke severity is a very strong discriminator of mortality risk, even in the absence of
other clinical information, whether used as a continuous or categorical risk determinant. ( J Am Heart Assoc 2012;1:42-50.)
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S troke is among the leading causes of death, disability, hos-pitalizations, and healthcare expenditures in the United
States.1 National quality profiling efforts have recently begun
to report hospital-level performance for Medicare beneficia-
ries, including 30-day mortality rates, for common medical
conditions including heart failure, acute myocardial infarc-
tion, and community-acquired pneumonia.2–5 There is grow-
ing interest in also reporting outcomes for Medicare benefi-
ciaries hospitalized with acute ischemic stroke.6 Risk adjust-
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ment is critical for accurately assessing and reporting clinical
outcomes.2–4 Stroke severity on admission is a powerful de-
terminate of functional outcomes in acute ischemic stroke.7–9
Editorial on p 6
The National Institutes of Health Stroke Scale (NIHSS), which
is a validated tool for assessing the initial stroke severity, has
been shown to predict mortality in acute ischemic stroke in
several prior studies.9–14 However, these studies have gen-
erally been confined to small numbers of patients from sin-
gle centers, select patients enrolled in randomized clinical
trials, studies outside the United States, or limited to eval-
uating in-hospital mortality. The relation of admission NIHSS
to 30-day mortality and its capability to discriminate risk in
Medicare beneficiaries with acute ischemic stroke have not
be well studied. Using data from ischemic stroke admissions
in the Get With The Guidelines-Stroke (GWTG-Stroke) Program
linked to Medicare data, the objectives of this study were to
(1) quantify the relation and risk discrimination of admission
NIHSS to 30-day mortality rates among Medicare beneficiaries
hospitalized with acute ischemic stroke and (2) identify cate-
gories of NIHSS that provide optimal discrimination of 30-day
mortality risk.
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Methods
Data Sources
Data from theGWTG-Stroke registrywas linkedwith enrollment
files and inpatient claims from the Centers forMedicare &Med-
icaid Services (CMS) for the period April 1, 2003, through De-
cember 31, 2006. Follow-up continued through 2007. The de-
sign, inclusion criteria, and data collection methods for GWTG-
Stroke have been described previously.15,16 Patients were el-
igible for inclusion in the GWTG-Stroke registry if they were
admitted for acute stroke. Trained hospital personnel ascer-
tained acute ischemic stroke admissions by either prospective
clinical identification, retrospective identification using Inter-
national Classification of Diseases (ICD)-9 discharge codes,
or a combination. Patient data abstracted by trained hospital
personnel included demographics, medical history, brain imag-
ing, in-hospital treatment and events, discharge treatment and
counseling, mortality, and discharge destination. All patient
data were de-identified before submission. All states and re-
gions of the United States were represented and a variety of
centers participated, from community hospitals to large ter-
tiary centers. Data on hospital-level characteristics (ie, bed
size, academic or nonacademic status, and geographic region)
were obtained from the American Hospital Association.17 All
participating institutions were required to comply with local
regulatory and privacy guidelines and, if applicable, to obtain
institutional review board approval. Outcome Sciences, Inc
(Cambridge, MA) served as the registry-coordinating center.
The Duke Clinical Research Institute (Durham, NC) served as
the data analysis center.
The CMS files (100% Medicare research identifiable files)
included data for all fee-for-service Medicare beneficiaries
aged ≥65 years who were hospitalized with a diagnosis of
acute stroke (ICD-9- 430.x, 431.x, 433.x, 434.x, and 436.x).
We merged patient data in the GWTG registry with Medicare
Part A inpatient claims, matching by admission and discharge
dates, hospital, date of birth, and sex using methods previously
described.16,18 From 222278 hospitalizations of patients aged
65 years or older in GWTG-Stroke, we matched 157039 pa-
tients (69%) to fee-for-service Medicare claims from 850 hospi-
tals. Patients in Medicare–managed care plans (15% to 25% of
the population depending on the region of the country) or other
types of insurance are not included in fee-for-service Medi-
care claims files and therefore cannot be matched.16,18 The
study population was further confined to patients with acute is-
chemic stroke (N=101801), first index stroke admission April
2003 or later, and the first index admission (N=94421). Hos-
pitals and patients from centers with <25 ischemic stroke
patients entered during the study period were excluded to min-
imize the likelihood of sampling error. This resulted in a study
population of 91134 acute ischemic stroke patients from 625
GWTG-Stroke hospitals.
The NIHSS score was documented in 33770 of these pa-
tients (37.1%) from 560 hospitals. For additional stability at
the hospital level, we further confined the analysis to hospi-
tals with at least 10 patients with NIHSS documented dur-
ing the study period. This resulted in a final study population
of 33102 patients from 404 participating hospitals. The de-
mographics, clinical characteristics, and geographic distribu-
tion of matched and unmatched acute ischemic stroke cases
were similar, except fewer patients were enrolled in GWTG-
Stroke from the Midwest compared with unmatched ischemic
stroke cases. The demographics, clinical characteristics, and
geographic distribution of patients with and without NIHSS
recorded were similar. The 30-day mortality was modestly
lower in the 33102 patients with NIHSS recorded (13.6%)
compared with the 57364 patients without NIHSS recorded
(14.6%), P<0.0001.
National Institutes of Health Stroke Scale
The NIHSS is a 15-item neurologic examination stroke scale
used to evaluate the effect of acute ischemic stroke on the
levels of consciousness, language, neglect, visual-field loss,
extraocular movement, motor strength, ataxia, dysarthria, and
sensory loss that provides a quantitative measure of stroke-
related neurologic deficit.7 The scale is designed to be a simple,
valid, and reliable tool that can be administered at the bedside
consistently by physicians, nurses, or therapists. A trained
observer rates the patient’s ability to answer questions and
perform activities. Ratings for each item are scored with 3 to
5 grades with 0 as normal. The NIHSS can be viewed online at
http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf.
The first recorded NIHSS score, as close to admission as
possible, was collected when available. Stroke team members
were highly encouraged, but not required, to complete training
and certification in the NIHSS. There were 2 patients (0.006%)
with NIHSS score recorded with a value >42 who were not
included in the analyses. There were also a few patients with
improbable NIHSS scores of 41 (N=14) (0.04%) and 42 (N=16)
(0.05%). Although NIHSS scores of 41 and 42 should be unob-
tainable among patients who are alive and most likely reflect
slight scale errors in patients with severe stroke severity, these
NIHSS scores were analyzed as recorded.
Outcome
The outcome of interest was all-cause mortality within 30 days
from time of admission. As with other studies of Medicare ben-
eficiaries, we obtained, with complete ascertainment, deaths
and dates of death from the CMS vital status files.16,18
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Statistical Analysis
We summarized baseline characteristics by whether the pa-
tient was alive or dead at 30 days using percentages for cate-
gorical variables and means and SDs for continuous variables.
For comparisons by group, we used chi-square tests for cate-
gorical variables and Wilcoxon tests for continuous variables.
Frequency histograms were used to describe the distribution
of NIHSS scores. NIHSS was analyzed as a continuous variable
as well as in categorical groups. We used classification and
regression tree methodology19 to determine the optimal cut
points for 30-day mortality by categorical grouping of NIHSS
ranging from 2 to 6 groups. We also analyzed a 3-category
grouping of the NIHSS found in a prior study to discriminate
6-month dependency outcomes.8 Discrimination by NIHSS as
a continuous variable and by categorical groups was assessed
by determining Wald chi square and the c statistic. A c statistic
of 1.0 indicates perfect prediction whereas a c statistic of 0.50
indicates prediction no better than chance alone. The observed
versus predicted mortality by NIHSS as a continuous variable
for 10 deciles of expected risk was plotted. Discrimination
by NIHSS as a continuous variable was also examined among
several clinically relevant subgroups. A previously derived and
validated GWTG-Stroke clinical risk prediction model for acute
ischemic stroke was used to evaluate the discrimination of a
clinical model without and with NIHSS added.16 This model in-
cluded patient characteristics (age, sex, race/ethnicity, med-
ical history of previous stroke or transient ischemic attack,
coronary heart disease [CAD], myocardial infarction, carotid
stenosis, chronic obstructive pulmonary disease, dementia,
diabetes, peripheral vascular disease, pneumonia, renal dys-
function, and hypertension), on-hour arrival time to hospital
(Monday through Friday 7 AM to 5 PM, yes/no), and Emergency
Medical Service transport. SAS software version 9.2 (SAS In-
stitute Inc, Cary, NC) was used for all analyses.
Results
There were 33102 acute ischemic stroke patients with NIHSS
documented in the study cohort. The patient characteristics
are shown in Table 1. The median age was 79 years, 56.5%
were women, and 83.3% were white. Prior stroke or transient
ischemic attack was present in 30.0% of patients. Comorbidi-
ties were common with hypertension in 77.5%, diabetes in
26.7%, coronary heart disease in 32.4%, and history of atrial
fibrillation or flutter in 24.5%. The NIHSS median score in this
population was 5 (25th to 75th percentile 2 to 12). The distri-
bution of NIHSS scores in this patient population are shown in
Figure 1. Close to two thirds of patients were reported to have
an admission NIHSS score of ≤8. Of the 404 GWTG-Stroke
hospitals included in this study, median bed size was 409, all
regions of the United States were represented, and nonaca-
demic hospitals accounted for 36.8% of admissions (Table 1).
There were 4496 deaths within the first 30 days (13.6%).
There were 2037 deaths that occurred during the index hos-
pitalization (inhospital mortality 6.4%). The patient and hos-
pital characteristics of those patients who died in the first
30 days compared with those who were alive are shown
in Table 1. Patients who died within 30 days from admis-
sion were older, female, more likely to be white, had a
higher frequency of atrial fibrillation, and prior history of
coronary artery disease (CAD). Patients who died were more
likely to have arrived by emergency medical services (EMS).
The median NIHSS was substantially higher among patients
who died compared with those who were alive at 30 days
(17 versus 4, P<0.0001). There were no significant differences
in hospital characteristics between patients who were alive or
dead in the first 30 days.
The relation between each score on the NIHSS and 30-
day mortality is shown in Figure 2. There was a graded near-
linear relationship between increases in the NIHSS and 30-day
mortality. The 30-daymortality ratewas 2.3% for patientswith a
score of 0 and was>75% for patients with a score of≥40. As a
continuous variable, NIHSS provided excellent discrimination
of 30-day mortality with a c-statistic 0.82, (95% confidence
interval [CI], 0.81–0.83). A calibration plot of observed and
expected 30-day mortality with NIHSS as a continuous variable
is shown in Figure 3. Categorizations of NIHSS by risk-tree
methodology with optimal cut points for 30-day mortality for
different group sizes are shown in Table 2. There was slightly
less discrimination with these categorical grouping with 4 or
more groups compared with NIHSS as a continuous variable,
with the risk-tree methodology selecting a categorization with
4 groups and cut points of 0 to 7, 8 to 13, 14 to 21, and 22 to
42. This allows identification on admission of acute ischemic
stroke patients at low (<10%), medium (10% to 20%), high
(20% to 40%), and very high (>40%) 30-day mortality risk as
shown in Figure 2 and Table 3. The c-statistic with this 4-group
categorical approach to NIHSS was 0.80 (95% CI, 0.79–0.80).
The 30-day mortality rates for these 4 NIHSS categories 0 to
7, 8 to 13, 14 to 21, and 22 to 42 were 4.2%, 13.9%, 31.6%,
and 53.5%, respectively (Table 3). Although patients with an
NIHSS score of 22 to 42 constitute only 8.2% of the cohort with
acute ischemic stroke, these patients account for close to one
third of all deaths. Alternative 3 group categories for NIHSS
are shown in Table 3. A categorization of patients with mild 0
to 5, moderate 6 to 13, and severe 14 to 42 stroke severity by
NIHSS produced groups with 30-day mortality rates of 3.6%,
11.6%, and 39.9% and a c-statistic of 0.79 (95%CI, 0.78–0.80).
NIHSS provided excellent discrimination of 30-day mortal-
ity for patients 65 to 79 years of age and those 80 or older,
men and women, and patients with and without prior stroke
or transient ischemic attack (Table 4). The clinical risk model
for Medicare beneficiaries based on demographics and clini-
cal variables without NIHSS had more modest discrimination
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Table 1. Patient and Hospital Characteristics of Medicare Beneficiaries in GTWG-Stroke Hospitals With Acute Ischemic Stroke
Overall and by Alive or Dead at 30 Days
Overall Cohort No Death Within 30 Days Death Within 30 Days
Variable (N=33102) (N=28606) (N=4496) P Value*
Age, y, median 79 79 83 <0.0001
25th–75th 73–85 72–84 78–88
Sex, male, % 43.6 44.3 38.9 <0.0001
Race/ethnicity, % <0.0001
Hispanic 2.5 2.6 1.9
Black 8.7 9.1 5.8
White 83.3 82.7 87.1
Arrival mode, % <0.0001
Emergency medical services 67.6 63.9 91.4
Private transport 32.4 36.1 8.6
Arrival time, off hours, % 53.4 53.3 54.3 0.1930
Atrial fibrillation/flutter, % 24.5 22.0 40.9 <0.0001
Previous stroke/TIA, % 30.0 29.8 31.6 0.0156
CAD/prior MI, % 32.4 31.6 37.8 <0.0001
Diabetes mellitus, % 26.7 26.8 25.7 0.1267
Peripheral vascular disease, % 5.5 5.3 6.7 0.0003
Hypertension, % 77.5 77.7 76.3 0.0293
Smoker, % 11.3 11.8 8.4 <0.0001
Dyslipidemia, % 36.4 37.9 26.8 <0.0001
Body mass index, kg/m2 25.8 26.0 24.4 <0.0001
25th–75th 22.8–30.0 23.0–29.8 21.5–28.0
NIHSS total score mean, (SD) 8.01 (7.88) 6.62 (6.67) 16.85 (9.18) <0.0001
Median 5 4 17
25th–75th 2–12 2–9 10–23
Discharge status, %
Home 36.6 41.9 2.9 <0.0001
Skilled nursing facility 24.0 24.5 20.4
Rehabilitation, % 26.7 30.2 4.7
Transfer to acute care facility 2.3 2.5 1.4
Left against medical advice 0.2 0.2 0.2
Hospice 3.8 0.6 24.7
Died inhospital 6.4 - 45.8
Ambulatory status† <0.0001
Ambulate independently 39.1 44.4 3.7
With assistance 34.3 37.8 10.1
Unable to ambulate 24.2 15.9 79.4
Hospital characteristic
No. of stroke discharges, % 0.8495
0–100 9.9 9.9 9.7
101–300 57.4 57.4 57.3
>300 32.7 32.7 33.0
Continued
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Table 1. Continued
Overall Cohort No Death Within 30 Days Death Within 30 Days
Variable (N=33102) (N=28606) (N=4496) P Value*
No. of beds, median 409 409 414 0.6929
25th–75th 279–580 279–580 279–580
Geographic region, % 0.9551
Northeast 25.8 25.7 26.0
Midwest 22.4 22.4 22.3
South 36.4 36.4 36.1
West 15.5 15.5 15.6
Hospital type, % 0.7908
Academic 63.2 63.2 63.4
Nonacademic 36.8 36.9 36.6
Missing 0.04 0.04 0.02
TJC primary stroke center, % 74.7 74.7 74.8 0.8329
GWTG indicates Get With The Guidelines; TIA, transient ischemic attack; CAD/prior MI, coronary artery disease or myocardial infarction; NIHSS, National Institutes of Health Stroke
Scale; SD, standard deviation; TJC, The Joint Commission.
∗Wilcoxon 2-sample test for continuous variables and chi-square test for categorical variables.
†Excludes patients who transferred out.
Figure 1. Distribution of NIHSS scores among Medicare ben-
eficiaries in GTWG-Stroke hospitals with acute ischemic stroke
patients alive at 30 days are shown in green and pa-
tients dead by 30 days shown in red. NIHSS indicates Na-
tional Institutes of Health Stroke Scale; GWTG, Get With The
Guidelines.
(c-statistic 0.71 [95% CI, 0.70–0.72]) and was substantially
outperformed by NIHSS alone (c-statistic 0.82 [95% CI, 0.81–
.83]). Adding the demographic and clinical variables from the
clinical risk model to NIHSS produced only small improvement
in discrimination beyond that obtained with NIHSS alone (c-
statistic 0.84 [95% CI, 0.84–0.85], difference 0.02, 95% CI,
0.02–0.03, P<0.0001).
Figure 2. Acute ischemic stroke 30-day mortality rates by NIHSS.
Standard error bars are displayed. NIHSS indicates National Institutes
of Health Stroke Scale.
Discussion
In assessing the relation of the NIHSS to 30-day mortality after
acute ischemic stroke among GWTG-Stroke Medicare benefi-
ciaries, this study finds that NIHSS is a very strong discrimina-
tor of mortality risk. There is a graded near-linear relationship
between first recorded NIHSS and higher 30-day mortality risk.
This study also demonstrates that with categorization of NIHSS
into 3 or 4 groups, acute ischemic stroke patients can be read-
ily identified as being at low, medium, or high risk for 30-day
mortality, even in the absence of any other demographic or
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Figure 3. Calibration plot of observed and predicted 30-day mortal-
ity by NIHSS as a continuous variable.
clinical variables. NIHSS provided excellent discrimination of
30-day mortality among multiple clinically relevant subgroups.
NIHSS as a continuous variable or in categories resulted in far
better discrimination of 30-day mortality risk then a clinical
model not including stroke severity. These findings highlight
the importance of a valid specific measure of stroke severity
as a determinate of mortality after acute ischemic stroke for
Medicare beneficiaries. Further, this study suggests that it may
be vital for optimal discrimination to include stroke severity for
risk stratification and risk adjustment in acute ischemic stroke.
The NIHSS was developed and subsequently validated as
a tool for assessing the initial stroke severity.20,21 It has sub-
sequently been shown to be predictive of a variety of stroke
functional outcomes.7–10 Stroke severity as indexed by NIHSS
has also been shown to be predictive of mortality after acute is-
chemic stroke.9–14 One study of 360 ischemic stroke patients
admitted to a single hospital in Taiwan identified admission
stroke severity as measured by NIHSS score as the strongest
predictor of 3-month mortality, with an odds ratio of 1.17 (95%
CI, 1.12–1.22) per point.12 Another study analyzed 479 pa-
tients admitted to a single center in Switzerland, advanced
age, and high NIHSS were the only independent predictor of
30-day mortality.11 A study from 7 centers in Germany found
NIHSS obtained within the first 6 hours of admission to be
highly predictive of 100-day survival (c-statistic 0.86).13 A prior
study for GWTG-Stroke showed that NIHSS was the strongest
predictive variable for inhospital mortality and substantially
improved the performance of a model based on clinical vari-
ables without stroke severity (c-statistic improved from 0.72
to 0.85).14 However, these studies were either small, drawn
from select patients enrolled in clinical trials, conducted in a
small number of centers outside the United States, or were
confined to inhospital mortality. The findings from the present
study, drawn from hundreds of hospitals from all regions of the
United States and tens of thousands of patients, substantially
extend these prior findings with follow-up to a standard 30-
day outcome, and may be viewed as having greater external
validity.
In the present study, a model with NIHSS alone without
other variables had a c-statistic of 0.82, a range where clinical
risk models are regarded to have genuine clinical utility for
individual decision making.22 This illustrates the very strong
relation between stroke severity and 30-day mortality. The
mortality risk discrimination capability of NIHSS, either in a
continuous or categorical variable, among Medicare beneficia-
ries with acute ischemic stroke compares very favorably to
other mortality prediction models incorporating the NIHSS or
other clinical measures of stroke severity (previously reported
c-statistics 0.79 to 0.86) and appear superior to models with
demographic/clinical variables without severity (previously re-
ported c-statistics 0.69 to 0.75).13,14,16,23 Measures of stroke
severity appear to be vital for optimal discrimination of mortal-
ity risk.
NIHSS was recorded in 37% of hospitalized acute ischemic
stroke patients during the time frame of this study. The time
and expertise needed to perform even a short standardized
stroke severity assessment is an important barrier that will
need to be further overcome. Recent data suggest that the
NIHSS is being documentedmore frequently. In the first 2 quar-
ters of 2011 in GWTG-Stroke, NIHSS was recorded in 61.1%
of acute ischemic stroke patients (data on file, Duke Clinical
Research Institute (DCRI)). Further study will be needed to de-
termine the best methods for ensuring high rates of use of
the NIHSS in routine clinical practice or whether other simpler
measures of stroke severity could be developed and substi-
tuted without substantial loss of prognostic information.
Limitations
There are several limitations in this study to consider. This
study includes only patients in fee-for-service Medicare and
thus does not include patients who were enrolled in managed
care, the uninsured, and patients younger than 65 years of age.
The relationship between NIHSS and 30-day mortality may dif-
fer among younger patients and those with different type of
insurance. However, it is Medicare beneficiaries with acute is-
chemic stroke for whom 30-day mortality rates that are being
considered for public reporting by CMS. The hospitals studied
are those participating in GWTG-Stroke and may not be repre-
sentative of all hospitals caring for patients with acute ischemic
stroke. Although hospital characteristics for GWTG-Stroke dif-
fer from the nation, the demographics and clinical character-
istics of Medicare beneficiaries in GWTG-Stroke have been
demonstrated to be very similar to the overall Medicare acute
ischemic stroke patient population.24 The analysis includes
only patients with NIHSS documented, which may introduce
selection bias, although differences in patient characteristic
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Table 2. Categorical Groupings of NIHSS to Best Discriminate 30-Day Mortality Risk
No. of Groupings Risk-Tree Cut Points for the Groupings Chi-Square for 30-Day Mortality c-Statistic (95% Confidence Intervals)
2 0–13, 14–42 5378 0.74 (0.74–0.75)
3 0–13, 14–21, 22–42 6069 0.75 (0.75–0.76)
4 0–7, 8–13, 14–21, 22–42 6418 0.80 (0.79–0.80)
5 0–7, 8–13, 14–18, 19–21, 22–42 6541 0.80 (0.79–0.81)
6 0–7, 8–13, 14–18, 19–21, 22–27, 28–42 6651 0.80 (0.79–0.81)
Original (NIHSS as continuous variable) 0, 1, 2, 3, 4, . . . ., 42 6856 0.82 (0.81–0.83)
NIHSS indicates National Institutes of Health Stroke Scale.
Classification and regression tree methodology (in R) with predetermined No. of nodes were applied to identify the categories of NIHSS. Larger chi-square statistic and c-statistic closer
to 1.0 indicates more optimal discrimination of risk.
and 30-day mortality of patients with or without NIHSS docu-
mented are small. Further the demographics, characteristics,
and 30-day mortality rates of patients with NIHSS in this study
were similar to the overall Medicare acute ischemic stroke pop-
ulation, suggesting these findings may have external validity.24
Study data were collected on the basis of the medical record
and depend on the accuracy and completeness of clinical doc-
umentation and chart abstraction. The NIHSS was analyzed
as assessed and documented in clinical practice, the precise
timing of NIHSS assessment was not collected, and the intra-
and interobserver reliability at participating hospitals was not
evaluated. Participating hospitals were encouraged to assess
NIHSS prospectively. However, it is possible that, for some
patients, NIHSS was determined retrospectively on the basis
of the documented neurological examination; though this ap-
proach has been shown to produce reliable and valid results.25
Any imprecision and lack of uniformity in scoring would be
expected to diminish, not enhance, the prognostic value of
NIHSS. We did not evaluate other metrics of stroke severity.
We also did not assess other important outcomes that may be
predicted by NIHSS including health-related quality of life, dis-
ability, patient satisfaction, rehospitalization, or other clinical
outcomes that may be of interest at 30 days or at longer time
intervals after stroke.
In summary, the NIHSS provides substantial prognostic in-
formation regarding mortality within the first 30 days among
Medicare beneficiaries with acute ischemic stroke. This index
of stroke severity is a very strong discriminator of mortality risk
whether evaluated as a continuous or categorical risk determi-
nate. With categorization of NIHSS into 3 or 4 groups, Medi-
care beneficiaries with acute ischemic stroke can be readily
identified as being at low, medium, and high risk for 30-day
Table 3. Relation of NIHSS Categories to 30-Day Mortality in Acute Ischemic Stroke
NIHSS Categories 30-Day Mortality Portion of Patients Portion of Deaths
0–7 4.2% (4.0%–4.5%) 61.3% 19.2%
8–13 13.9% (13.0%–14.8%) 17.1% 17.4%
14–21 31.6% (30.2%–32.9%) 13.4% 31.1%
22–42 53.5% (51.7%–55.4%) 8.2% 32.3%
c-statistic 0.80 (0.79–0.80)
0–7 4.2% (4.0%–4.5%) 61.3% 19.2%
8–13 13.9% (13.0%–14.8%) 17.1% 17.4%
14–42 39.9% (38.8%–41.0%) 21.6% 63.4%
c-statistic 0.79 (0.78–0.79)
0–5* 3.6% (3.3%–3.9%) 51.7% 13.7%
6–13* 11.6% (11.0%–12.3%) 26.7% 22.9%
14–42* 39.9% (38.8%–41.0%) 21.6% 63.4%
c-statistic 0.79 (0.78–0.80)
NIHSS indicates National Institutes of Health Stroke Scale.
*This categorization derived from reference 8.
The 95% confidence intervals are shown in parentheses.
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Table 4. NIHSS Discrimination of 30-Day Mortality Risk in
Clinically Relevant Subgroups
Chi-Square c-Statistic
Patient for 30-Day (95% Confidence
Subgroups Mortality Intervals)
Age <80 y (N=17020) 2539.4 0.82 (0.81–0.83)
Age ≥ 80 y (N=16080) 3558.7 0.81 (0.80–0.82)
Men (N=14417) 2588.1 0.81 (0.79–0.82)
Women (N=18683) 3913.6 0.83 (0.82–0.83)
Prior stroke/TIA (N=9886) 1820.2 0.81 (0.79–0.82)
No prior stroke/TIA (N=23047) 4720.0 0.82 (0.82–0.83)
NIHSS indicates National Institutes of Health Stroke Scale; TIA, transient ischemic
attack.
NIHSS analyzed as a continuous variable.
mortality. These findings suggest that it may be critical to col-
lect and include stroke severity for optimal risk stratification
and risk adjustment of 30-day mortality for Medicare benefi-
ciaries with acute ischemic stroke.
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